(5)6,000 chickens killed by bird flu in Yamaguchi Pref.

(5)6,000 chickens killed by bird flu in Yamaguchi Pref.

TOKYO, Japan - Masako Kurimoto, chief of the Health Administration Section at the Health, Labor and Welfare Ministry, briefs reporters on the outbreak of bird flu in Yamaguchi Prefecture at a press conference on Jan. 12.

  • Product Code
  • ILEA001100782
  • Registered date
  • 2004/1/12 00:00:00
  • Credit
  • Kyodo / Kyodo News Images
  • Media source
  • 2004 Kyodo News
  • Media size
  • 1864 × 1228 pixel
  • Resolution
  • dpi
  • Deployment size
  • 578.45(KB)*
  • Special instruction

*File size when opened in Photoshop, etc.

Similar Images & Videos
    Japan finance minister Suzuki on currency market

    Japan finance minister Suzuki on currency market

    Japanese Finance Minister Shunichi Suzuki holds a press conference at the ministry in Tokyo on July 12, 2024. He declined to comment on whether Japan had intervened in the currency market overnight to shore up the yen against the U.S. dollar.
      Senior Japan finance ministry official on exchange market

      Senior Japan finance ministry official on exchange market

      Japanese Vice Finance Minister for International Affairs Masato Kanda (far R) meets the press at the Finance Ministry building in Tokyo on July 12, 2024, after the U.S. dollar's plunge against the yen in New York overnight. Japan's top currency diplomat Kanda told reporters he would not comment on whether authorities intervened in the currency market.
        Entrance ceremony for new ministry officials

        Entrance ceremony for new ministry officials

        New recruits at the Ministry of Health, Labor and Welfare attend an entrance ceremony at the ministry in Tokyo on April 1, 2024, the first day of the new business year. (Pool photo)
          New Year meeting of major business lobbies

          New Year meeting of major business lobbies

          Ken Kobayashi, chairman of the Japan Chamber of Commerce and Industry, holds a press conference after attending a New Year meeting hosted by Japan's three major business organizations in Tokyo on Jan. 5, 2024.
            BOJ chief Kuroda after policy-setting meeting

            BOJ chief Kuroda after policy-setting meeting

            Bank of Japan Governor Haruhiko Kuroda holds a press conference at the BOJ's headquarters in Tokyo on Jan. 18, 2023, after the central bank decided at a two-day policy meeting to maintain its ultralow rate policy. Kuroda said he sees no need to further widen the trading band for 10-year Japanese government bond yields. (Pool photo)
              BOJ chief Kuroda after policy-setting meeting

              BOJ chief Kuroda after policy-setting meeting

              Bank of Japan Governor Haruhiko Kuroda holds a press conference at the BOJ's headquarters in Tokyo on Jan. 18, 2023, after the central bank decided at a two-day policy meeting to maintain its ultralow rate policy. Kuroda said he sees no need to further widen the trading band for 10-year Japanese government bond yields. (Pool photo)
                BOJ chief Kuroda after policy-setting meeting

                BOJ chief Kuroda after policy-setting meeting

                Bank of Japan Governor Haruhiko Kuroda holds a press conference at the BOJ's headquarters in Tokyo on Jan. 18, 2023, after the central bank decided at a two-day policy meeting to maintain its ultralow rate policy. Kuroda said he sees no need to further widen the trading band for 10-year Japanese government bond yields. (Pool photo)
                  U.S. regulators OK Alzheimer's drug developed by Japan's Eisai

                  U.S. regulators OK Alzheimer's drug developed by Japan's Eisai

                  Japanese pharmaceutical maker Eisai Co. CEO Haruo Naito holds a press conference in Tokyo on Jan. 7, 2023, a day after the U.S. Food and Drug Administration approved lecanemab, an Alzheimer's drug developed by his company and U.S. firm Biogen Inc. for treatment in the early stage of the fatal, brain-robbing disease.
                    U.S. regulators OK Alzheimer's drug developed by Japan's Eisai

                    U.S. regulators OK Alzheimer's drug developed by Japan's Eisai

                    Japanese pharmaceutical maker Eisai Co. CEO Haruo Naito holds a press conference in Tokyo on Jan. 7, 2023, a day after the U.S. Food and Drug Administration approved lecanemab, an Alzheimer's drug developed by his company and U.S. firm Biogen Inc. for treatment in the early stage of the fatal, brain-robbing disease.
                      U.S. regulators OK Alzheimer's drug developed by Japan's Eisai

                      U.S. regulators OK Alzheimer's drug developed by Japan's Eisai

                      Japanese pharmaceutical maker Eisai Co. CEO Haruo Naito holds a press conference in Tokyo on Jan. 7, 2023, a day after the U.S. Food and Drug Administration approved lecanemab, an Alzheimer's drug developed by his company and U.S. firm Biogen Inc. for treatment in the early stage of the fatal, brain-robbing disease.